Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia

被引:47
|
作者
Anderson, Stacey M. [1 ]
Buckingham, Bruce A. [2 ]
Breton, Marc D. [1 ]
Robic, Jessica L. [1 ]
Barnett, Charlotte L. [1 ]
Wakeman, Christian A. [1 ]
Oliveri, Mary C. [1 ]
Brown, Sue A. [1 ]
Ly, Trang T. [2 ]
Clinton, Paula K. [2 ]
Hsu, Liana J. [2 ]
Kingman, Ryan S. [2 ]
Norlander, Lisa M. [2 ]
Loebner, Sarah E. [2 ]
Reuschel-DiVirglio, Suzette [2 ]
Kovatchev, Boris P. [1 ]
机构
[1] Univ Virginia, Ctr Diabet Technol, POB 400888, Charlottesville, VA 22908 USA
[2] Stanford Univ, Dept Pediat, Div Pediat Endocrinol & Diabet, Sch Med, Stanford, CA 94305 USA
关键词
Type; 1; diabetes; Hypoglycemia; Artificial pancreas; Closed-loop systems; INSULIN DELIVERY; HOME-USE; ADULTS; MULTICENTER; ADOLESCENTS; DISEASE; IDDM;
D O I
10.1089/dia.2019.0018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Typically, closed-loop control (CLC) studies excluded patients with significant hypoglycemia. We evaluated the effectiveness of hybrid CLC (HCLC) versus sensor-augmented pump (SAP) in reducing hypoglycemia in this high-risk population. Methods: Forty-four subjects with type 1 diabetes, 25 women, 37 +/- 2 years old, HbA1c 7.4% +/- 0.2% (57 +/- 1.5 mmol/mol), diabetes duration 19 +/- 2 years, on insulin pump, were enrolled at the University of Virginia (N = 33) and Stanford University (N = 11). Eligibility: increased risk of hypoglycemia confirmed by 1 week of blinded continuous glucose monitor (CGM); randomized to 4 weeks of home use of either HCLC or SAP. Primary/secondary outcomes: risk for hypoglycemia measured by the low blood glucose index (LBGI)/CGM-based time in ranges. Results: Values reported: mean +/- standard deviation. From baseline to the final week of study: LBGI decreased more on HCLC (2.51 +/- 1.17 to 1.28 +/- 0.5) than on SAP (2.1 +/- 1.05 to 1.79 +/- 0.98), P < 0.001; percent time below 70 mg/dL (3.9 mmol/L) decreased on HCLC (7.2% +/- 5.3% to 2.0% +/- 1.4%) but not on SAP (5.8% +/- 4.7% to 4.8% +/- 4.5%), P = 0.001; percent time within the target range 70-180 mg/dL (3.9-10 mmol/L) increased on HCLC (67.8% +/- 13.5% to 78.2% +/- 10%) but decreased on SAP (65.6% +/- 12.9% to 59.6% +/- 16.5%), P < 0.001; percent time above 180 mg/dL (10 mmol/L) decreased on HCLC (25.1% +/- 15.3% to 19.8% +/- 10.1%) but increased on SAP (28.6% +/- 14.6% to 35.6% +/- 17.6%), P = 0.009. Mean glucose did not change significantly on HCLC (144.9 +/- 27.9 to 143.8 +/- 14.4 mg/dL [8.1 +/- 1.6 to 8.0 +/- 0.8 mmol/L]) or SAP (152.5 +/- 24.3 to 162.4 +/- 28.2 [8.5 +/- 1.4 to 9.0 +/- 1.6]), P = ns. Conclusions: Compared with SAP therapy, HCLC reduced the risk and frequency of hypoglycemia, while improving time in target range and reducing hyperglycemia in people at moderate to high risk of hypoglycemia.
引用
收藏
页码:356 / 363
页数:8
相关论文
共 50 条
  • [31] Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial
    Kovatchev, Boris P.
    Kollar, Laura
    Anderson, Stacey M.
    Barnett, Charlotte
    Breton, Marc D.
    Carr, Kelly
    Gildersleeve, Rachel
    Oliveri, Mary C.
    Wakeman, Christian A.
    Brown, Sue A.
    LANCET DIGITAL HEALTH, 2020, 2 (02): : E64 - E73
  • [32] Sociodemographic inequities and use of hybrid closed-loop systems associated with obesity in youth with type 1 diabetes
    Azova, Svetlana
    Laffel, Lori
    Lennerz, Belinda S.
    Petty, Carter R.
    Wolfsdorf, Joseph
    Rhodes, Erinn T.
    Garvey, Katharine
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 221
  • [33] Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country
    Proietti, Adrian
    Raggio, Marcela
    Paz, Maria
    Rubin, Graciela
    Kabakian, Maria
    Saleme, Antonio
    Grosembacher, Luis
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (03) : 220 - 226
  • [34] The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting
    Gardner, Daphne
    Lakkad, Mrinmayee
    Qiu, Zhiyu
    Inoue, Yuta
    Chandran, Suresh Rama
    Wherry, Kael
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (05) : 324 - 334
  • [35] Closed-Loop Control Without Meal Announcement in Type 1 Diabetes
    Cameron, Faye M.
    Ly, Trang T.
    Buckingham, Bruce A.
    Maahs, David M.
    Forlenza, Gregory P.
    Levy, Carol J.
    Lam, David
    Clinton, Paula
    Messer, Laurel H.
    Westfall, Emily
    Levister, Camilla
    Xie, Yan Yan
    Baysal, Nihat
    Howsmon, Daniel
    Patek, Stephen D.
    Bequette, B. Wayne
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (09) : 527 - 532
  • [36] Hypoglycemia and Hyperglycemia According to Type of Diabetes: Observations During Fully Closed-Loop Insulin Delivery in Adults With Type 1 and Type 2 Diabetes
    Kadiyala, Nithya
    Wilinska, Malgorzata E.
    Daly, Aideen B.
    Nwokolo, Munachiso
    Lakshman, Rama
    Hartnell, Sara
    Ware, Julia
    Allen, Janet M.
    Cezar, Alina
    Evans, Mark L.
    Hovorka, Roman
    Boughton, Charlotte K.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [37] Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Glycemic Outcomes with Closed-Loop Insulin Delivery
    Lakshman, Rama
    Najami, Mazin
    Allen, Janet M.
    Ware, Julia
    Wilinska, Malgorzata E.
    Hartnell, Sara
    Thankamony, Ajay
    Randell, Tabitha
    Ghatak, Atrayee
    Besser, Rachel E. J.
    Elleri, Daniela
    Trevelyan, Nicola
    Campbell, Fiona M.
    Hovorka, Roman
    Boughton, Charlotte K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (03) : 198 - 202
  • [38] Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management
    Adams, Rebecca N.
    Tanenbaum, Molly L.
    Hanes, Sarah J.
    Ambrosino, Jodie M.
    Ly, Trang T.
    Maahs, David M.
    Naranjo, Diana
    Walders-Abramson, Natalie
    Weinzimer, Stuart A.
    Buckingham, Bruce A.
    Hood, Korey K.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (10) : 648 - 653
  • [39] Safe and effective use of a hybrid closed-loop system from diagnosis in children under 18 months with type 1 diabetes
    Tseretopoulou, Xanthippi
    Viswanath, Vidya
    Hartnell, Sara
    Ware, Julia
    Thankamony, Ajay
    Webb, Emma A.
    Hysted, Helen
    Ashford, Jennifer
    Hendriks, Emile
    Teoh, Yun
    Williams, Rachel M.
    PEDIATRIC DIABETES, 2022, 23 (01) : 90 - 97
  • [40] Comparative Effectiveness of Hybrid Closed-Loop Automated Insulin Delivery Systems Among Patients with Type 1 Diabetes
    Folk, Sara
    Zappe, Janet
    Wyne, Kathleen
    Dungan, Kathleen M.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,